Da Hee Han, PharmD

All articles by Da Hee Han, PharmD

Filgotinib Meets Primary End Points in 2 Rheumatoid Arthritis Studies

March 29, 2019

Gilead Sciences and Galapagos NV announced that filgotinib met the primary and major secondary endpoints in the phase 3 FINCH 1 rheumatoid arthritis, as well as the primary endpoint in the phase 3 FINCH 3 study in methotrexate (MTX)-naive rheumatoid arthritis patients.

Pain Management

Oral NSAIDs for Knee OA: Duration of Efficacy, Time to Adverse Event Onset Examined

Da Hee Han, PharmD

March 28, 2019

A systematic review and meta-analysis published in Arthritis Care & Research aimed to assess the duration of efficacy, as well as the onset of adverse events, associated with oral nonsteroidal anti-inflammatory drugs (NSAIDS) used in the treatment of knee osteoarthritis (OA). To investigate these outcomes, researchers conducted a literature search which identified 72 randomized controlled…

Next post in Pain Management

Da Hee Han, PharmD

All articles by Da Hee Han, PharmD

Filgotinib Meets Primary End Points in 2 Rheumatoid Arthritis Studies

Oral NSAIDs for Knee OA: Duration of Efficacy, Time to Adverse Event Onset Examined

Opioid Prescriptions Dropped for New Users From 2012 to 2017